Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics
| Project/Area Number |
25460202
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Hamada Akinobu 国立研究開発法人国立がん研究センター, その他部局等, 分野長 (00322313)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAMURA Kenji 国立研究開発法人国立がん研究センター, 中央病院, 科長 (60340783)
FUJIWARA Yutaka 国立研究開発法人国立がん研究センター, 中央病院, 医長 (70464261)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 薬物動態 / 個別化医療 / ABCB1 / クリゾチニブ / エリブリン / 薬理遺伝学 / 臨床薬理 / 薬理遺伝学的解析 / LC/MS/MS |
|---|
| Outline of Final Research Achievements |
In 78 non-small cell lung cancer (ALK fusion gene-positive) patients treated with crizotinib, the trough plasma concentration of crizotinib did not correlate the development of liver dysfunction and QT prolongation. On the other hand, the association of ABCB1 1236TT-2677TT-3435TT genotype with crizotinib pharamcokinetics was observed.
In 29 inoperable or recurrent breast cancer patient treated with eribulin the results of interim analysis suggest that the development of over grade 3 myelosuppression may be associated with the plasma concentration of eribulin after 24 hour administration.
|
Report
(4 results)
Research Products
(2 results)
